CHOSA enters into an agreement with a CLIA-certified laboratory partner for Platin-DRP® in the USA - first revenue expected summer 2027

CHOSA secures US lab partner for Platin-DRP, targets first revenue in summer 2027.

What the company is saying

CHOSA Oncology AB announces a signed agreement with a CLIA-certified laboratory to develop and validate its Platin-DRP test as a laboratory-developed test for US commercialization. The company frames this as a critical milestone for bringing its platinum-response biomarker to clinical use in the United States. Management emphasizes the test’s clinical validation, citing statistically significant survival benefits from the Phase III SPLENDOUR trial and retrospective studies. CEO Peter Buhl Jensen highlights the estimated US market potential of over 250,000 tests per year, but projects only 300-500 tests sold in the first year. The announcement also spotlights ongoing collaboration with Mount Sinai Hospital in New York, with an initial read-out expected in Q1 2027. The tone is confident, focusing on the ambition to enable more personalized lung cancer treatment and on the company’s intent to pursue further partnerships or sublicensing agreements for its oncology assets.

What the data suggests

The agreement with a CLIA-certified laboratory is a concrete operational step, but revenue from Platin-DRP testing in the US is not expected until summer 2027 and is contingent on successful analytical validation and regulatory implementation. The SPLENDOUR trial included 82 advanced NSCLC patients and showed median overall survival of 16.9 months for high Platin-DRP scorers versus 5.5 months for low scorers. In a separate retrospective study, the top 10% of Platin-DRP scorers had a 3-year survival rate of 90%, while the lowest 10% had only 40%. The company claims a US market potential of more than 250,000 tests per year, but expects only 300-500 tests sold in the first year, and provides no evidence or methodology for these projections. The Mount Sinai study involves 94 US patient samples, with results expected in Q1 2027. All disclosed figures are forward-looking except for clinical trial data; there are no current revenue, cash, or profit figures. The announcement demonstrates scientific progress but leaves commercial uptake, pricing, and payer acceptance unaddressed.

Analysis

The announcement is upbeat, highlighting a new agreement with a CLIA-certified lab and referencing promising clinical data. However, most commercial benefits are forward-looking: first US revenues are not expected until summer 2027 (over 18 months away), and this is contingent on successful analytical validation and regulatory implementation. The company cites large market potential (250,000 tests/year) and first-year sales estimates (300-500 tests), but provides no supporting methodology or evidence for these projections. While the clinical trial results are specific and credible, there is no disclosure of current revenue, profit, or cash flow, and no evidence of signed commercial contracts or partnerships beyond the lab agreement. The capital intensity flag is triggered by the need for substantial laboratory development and validation work before any revenue is realized. The gap between narrative and evidence is most pronounced in the commercial projections and partnership ambitions, which remain aspirational.

Risk flags

• ●Commercialisation is contingent on successful analytical validation and CLIA regulatory implementation, both of which are complex and can introduce delays or failures. The company explicitly warns that additional technical or documentation requirements may arise, which could affect the projected timeline.
• ●The projected US market size of over 250,000 tests per year and first-year sales of 300-500 tests are unsupported by disclosed market research, customer commitments, or external validation, raising questions about demand and adoption.
• ●No current revenue, cash, or cost figures are disclosed, making it impossible to assess the company’s financial runway or ability to fund ongoing development and commercialisation activities.
• ●The Mount Sinai retrospective study is still in progress, with an initial read-out not expected until Q1 2027, so clinical validation in the chemo-immunotherapy setting remains unproven and could impact future adoption.
• ●The announcement references ambitions for partnership or sublicensing agreements for LiPlaCis and DRP, but provides no evidence of negotiations, counterparties, or signed deals, making these potential value drivers speculative.

Bottom line

CHOSA Oncology AB’s agreement with a CLIA-certified US laboratory is a necessary step toward commercialising Platin-DRP, but no revenue is expected before summer 2027 and this is dependent on successful validation and regulatory clearance. Clinical trial data show strong survival benefits for high Platin-DRP scorers, but the company’s commercial projections—250,000 test market potential and 300-500 first-year sales—are not substantiated by customer data or external research. The Mount Sinai study could extend validation into chemo-immunotherapy regimens, but results are months away. No current financials or operational metrics are disclosed, leaving the company’s funding position and near-term risk profile unclear. The most important takeaway is that while scientific progress is evident, commercial and financial upside remains distant and highly contingent on future milestones. Investors should focus on evidence of analytical validation, regulatory progress, and early customer traction as the next meaningful catalysts.

Announcement summary

(FSE:W5L) CHOSA Oncology AB has entered into an agreement with a CLIA-certified laboratory to develop and validate Platin-DRP® as a laboratory-developed test (LDT) for US commercialization. The company expects first revenues from Platin-DRP® testing in the United States in summer 2027, contingent on successful analytical validation and implementation under the laboratory's CLIA certification. The CLIA programme builds on clinical results from CHOSA's collaboration with ETOP and EORTC, specifically the randomized Phase III SPLENDOUR trial, which included 82 patients with advanced NSCLC treated with cisplatin or carboplatin. Results presented at the European Lung Cancer Congress in March 2026 showed that patients with high Platin-DRP® scores had a median overall survival of 16.9 months, compared to 5.5 months for those with low scores. The company estimates the US market potential at more than 250,000 Platin-DRP® tests per year and expects to sell 300-500 tests in the first year. In a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery, patients with the 10% highest Platin-DRP® scores had a 3-year survival of 90%, while those with the lowest 10% scores had a 3-year survival of only 40%. CHOSA is also conducting a retrospective study with Mount Sinai Hospital in New York to evaluate Platin-DRP® in patients with advanced NSCLC treated with platinum chemotherapy combined with PD-1/PD-L1 immunotherapy, using 94 tumour biopsy samples from US patients. An initial read-out from this study is expected in the first quarter of 2027. Platin-DRP® is a gene expression-based biomarker designed to predict response to platinum-based chemotherapy, and CHOSA holds worldwide rights to the test. The company intends to enter into partnership or sublicensing agreements for LiPlaCis® and the DRP®. DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics Ltd and LiPlasome Pharma ApS. Peter Buhl Jensen is the CEO of CHOSA Oncology AB.

Disagree with this article?